Skip to content
OpenCapital
Get started

Harmony Biosciences Holdings, Inc. HRMY Proceeds From Sale And Maturity Of Available For Sale Securities

Proceeds From Sale And Maturity Of Available For Sale Securities at other companies

Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
——
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
——
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
——

Other financials

Income statement

See full
Revenue$215.4M+16.6%
Gross profit$170.9M+11.9%
Operating income$37.3M-33.7%
Net income$32.5M-28.7%
EPS (diluted)$0.55-29.5%

Balance sheet

See full
Cash & equivalents$589.4M+20.5%
Total debt$164.6M-7.2%
Total equity$910.3M+26.3%
Total assets$1.3B+20.5%

Cash flow

See full
Operating cash flow$27.8M-18.3%
CapEx$107.0K-79.1%
Free cash flow$126.0M+67.9%

Valuation

See full
Market cap$1.99B-14.9%

Profitability

See full
Gross margin76.5%-1.8pp
Operating margin21.1%-5.1pp
Net margin16.2%-4.3pp
FCF margin40.1%+9.5pp

Returns & leverage

See full
Return on equity17.9%-6.9pp
Debt / equity0.2×-0.1×
Current ratio3.6×-0.1×

Where this comes from

Reported directly by Harmony Biosciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: Harmony Biosciences Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harmony Biosciences Holdings, Inc.'s proceeds from sale and maturity of available for sale securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Harmony Biosciences Holdings, Inc.'s proceeds from sale and maturity of available for sale securities?
Harmony Biosciences Holdings, Inc. (HRMY) reported proceeds from sale and maturity of available for sale securities of $27.35M in Q1 2026.
How has Harmony Biosciences Holdings, Inc.'s proceeds from sale and maturity of available for sale securities changed year-over-year?
Harmony Biosciences Holdings, Inc.'s proceeds from sale and maturity of available for sale securities increased by 26.5% year-over-year, from $21.62M to $27.35M.
What is the long-term trend for Harmony Biosciences Holdings, Inc.'s proceeds from sale and maturity of available for sale securities?
Over 2 years (2023 to 2025), Harmony Biosciences Holdings, Inc.'s proceeds from sale and maturity of available for sale securities has grown at a -17.2% compound annual growth rate (CAGR), from $118.31M to $81.06M.